Advertisement

Intensive Care Medicine

, Volume 34, Issue 3, pp 511–517 | Cite as

Terlipressin as a rescue therapy for catecholamine-resistant septic shock in children

  • Dincer YildizdasEmail author
  • Hacer Yapicioglu
  • Umit Celik
  • Yasar Sertdemir
  • Emre Alhan
Pediatric Original

Abstract

Objective

To evaluate the effect of terlipressin on oxygenation, PaO2/FIO2, heart rate, mean arterial pressure, and mortality in children with septic shock refractory to high doses of dopamine/dobutamine and adrenaline.

Design and setting

A randomized, nonblind study in the pediatric intensive care unit of a university hospital.

Patients and measurements

We studied 58 children with septic shock and refractory hypotension despite fluid loading and high doses of catecholamines, randomly enrolled to terlipressin (TP, n = 30) or control (n = 28). TP was administered as intravenous bolus doses of 20 μg/kg every 6 h for a maximum of 96 h. Hemodynamic changes, PaO2/FIO2 rates, length of stay, and mortality rate in PICU were recorded prospectively.

Results

Mean arterial pressure and PaO2/FIO2 significantly increased, and heart rate significantly decreased 30 min after each TP treatment, but mortality did not differ from control (67.3% vs. 71.4%). Mean stay in the PICU was shorter in the TP group (13.4 ± 7.9 vs. 20.2 ± 9.7 days and was longer among nonsurvivors of the TP group vs. control (10.4 ± 6.9 vs. 6.2 ± 3.4 days). Blood urea nitrogen, creatinine, AST, ALT, and urine output of patients in the TP group did not change after terlipressin.

Conclusions

Although terlipressin infusion had no effect on mortality, it significantly increases mean arterial pressure, PaO2/FIO2, and survival time in nonsurvivors. Terlipressin seems to cause no adverse effect but warrants further evaluation as a rescue therapy in refractory septic shock.

Keywords

Terlipressin Epinephrine Septic shock Children 

References

  1. 1.
    Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC (2003) The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 167:695–701PubMedCrossRefGoogle Scholar
  2. 2.
    Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 45:588–595CrossRefGoogle Scholar
  3. 3.
    Meyer J, Booke M, Waurick R, Prien T, van Aken H (1996) Nitric oxide synthase inhibition restores vasopressor effects of norepinephrine in ovine hyperdynamic sepsis. Anesth Analg 83:1009–1013PubMedCrossRefGoogle Scholar
  4. 4.
    Holmes CL, Patel BM, Russell JA (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989–999PubMedCrossRefGoogle Scholar
  5. 5.
    Landry DW, Oliver JA (1992) The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 89:2071–2074PubMedCrossRefGoogle Scholar
  6. 6.
    Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent J-L, Levy MM (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–870PubMedCrossRefGoogle Scholar
  7. 7.
    Dellinger RP (2003) Cardiovascular management of septic shock. Crit Care Med 31:946–955PubMedCrossRefGoogle Scholar
  8. 8.
    Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent J-L, Zanotti-Cavazzoni S (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32:1928–1948PubMedCrossRefGoogle Scholar
  9. 9.
    Martin C, Papazian L, Perrin G, Saux P, Gouin F (1993) Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103:1826–1831PubMedCrossRefGoogle Scholar
  10. 10.
    Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD (1987) A reappraisal of norepinehrine therapy in human septic shock. Crit Care Med 15:134–137PubMedCrossRefGoogle Scholar
  11. 11.
    Reinhart K, Saka SG, Meier-Hellman A (2000) Haemodynamic management of a patient with septic shock. Eur J Anaeasthesiol 17:6–17CrossRefGoogle Scholar
  12. 12.
    Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG (1989) Effect of dopamine versus norepinephrine on hemodynamic in septic shock: emphasis on right ventricular performance. Chest 95:1282–1288PubMedCrossRefGoogle Scholar
  13. 13.
    Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282PubMedCrossRefGoogle Scholar
  14. 14.
    Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, Erlinger S, Lebrec D (1998) Beneficial effects of 2 day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 29:565–570PubMedCrossRefGoogle Scholar
  15. 15.
    Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582PubMedCrossRefGoogle Scholar
  16. 16.
    O'Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrine resistant septic shock. Lancet 359:1209–1210PubMedCrossRefGoogle Scholar
  17. 17.
    Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alanso N, Martinon-Sanchez JM (2004) Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 30:477–480PubMedCrossRefGoogle Scholar
  18. 18.
    Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M, Barzilay Z, Paret G (2004) Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock. Pediatr Crit Care Med 5:116–118PubMedCrossRefGoogle Scholar
  19. 19.
    Peters M, Booth RA, Petros AJ (2004) Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatr Crit Care Med 5:112–115PubMedCrossRefGoogle Scholar
  20. 20.
    Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P (2004) Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30:597–604PubMedCrossRefGoogle Scholar
  21. 21.
    Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C (2004) Terlipressin in catecholamine-resistant septic shock patients. Shock 22:314–319PubMedCrossRefGoogle Scholar
  22. 22.
    Matok I, Vard A, Efrati O, Rubinshtein M, Vishne T, Leibovitch L, Adam M, Barzilay Z, Paret G (2005) Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 23:305–310PubMedCrossRefGoogle Scholar
  23. 23.
    Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C, RETSPED Working Group of the Spain Society of Pediatric Intensive Care (2006) Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 10:1–8Google Scholar
  24. 24.
    Siegfried BH, Henderson TO (2002) Cardiology. In: Gunn VL, Nechyba C (eds) The Harriet Lane Handbook, 16th edn. Elsevier Science, Philadelphia, pp 123–168Google Scholar
  25. 25.
    Greenfield MM (2002) Pulmonology. In: Gunn VL, Nechyba C (eds) The Harriet Lane Handbook, 16th edn. Elsevier Science, Philadelphia, pp 513–527Google Scholar
  26. 26.
    Hayden WR (1994) Sepsis terminology in pediatrics. J Pediatr 124:657–658PubMedGoogle Scholar
  27. 27.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 19:973–976Google Scholar
  28. 28.
    Abboud FM, Floras JS, Aylward PE, Guo GB, Gupta BN, Schmid PG (1990) Role of vasopressin in cardiovascular and blood pressure regulation. Blood Vessels 27:106–115PubMedGoogle Scholar
  29. 29.
    Sharshar T, Blanchard A, Paillard M, Paphael JC, Gajdos P, Annane D (2003) Circulating vasopressin levels in septic shock. Crit Care Med 31:1752–1758PubMedCrossRefGoogle Scholar
  30. 30.
    Delmas A, Leone M, Rousseau S, Albanese J, Martin C (2005) Clinical review: vasopressin and terlipressin in septic shock patients. Crit Care 9:212–222PubMedCrossRefGoogle Scholar
  31. 31.
    Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low dose of vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703PubMedGoogle Scholar
  32. 32.
    Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR (2003) Arginine vasopressin in advanced vasodilatory shock. A prospective, randomized, controlled study. Circulation 107:2313–2319PubMedCrossRefGoogle Scholar
  33. 33.
    Albanase J, Leone M, Delmas A, Martin C (2005) Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 33:1897–1902CrossRefGoogle Scholar
  34. 34.
    Undesser KP, Hasser EM, Haywood JR, Johnson AK, Bishop VS (1985) Interactions of vasopressin with the postrema in arterial baroreflex function in conscious rabbits. Circ Res 56:410–417PubMedGoogle Scholar
  35. 35.
    Evora PR, Pearswon PJ, Schaff HV (1993) Arginine vasopressin induces endothelium-dependent vasodilation of pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 103:1241–1245PubMedCrossRefGoogle Scholar
  36. 36.
    Mutlu GM, Factor P (2004) Role of vasopressin in the management of septic shock. Intensive Care Med 30:1276–1291PubMedGoogle Scholar
  37. 37.
    Edwards RM, Trizna W, Kinter LB (1989) Renal effects of vasopressin and vasopressin antagonists. Am J Physiol 256:F274–278PubMedGoogle Scholar
  38. 38.
    Ceneviva G, Paschall AJ, Maffei F, Carcillo JA (1998) Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 102:e19PubMedCrossRefGoogle Scholar
  39. 39.
    Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M (1996) Epidemiology of sepsis and multiorgan dysfunction syndrome in children. Chest 109:1033–1037PubMedCrossRefGoogle Scholar
  40. 40.
    Goh A, Chan PWK, Lum LCS (1999) Sepsis, severe sepsis and septic shock in paediatric multiorgan dysfunction syndrome. J Paediatr Child Health 35:488–492PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Dincer Yildizdas
    • 1
    Email author
  • Hacer Yapicioglu
    • 2
  • Umit Celik
    • 3
  • Yasar Sertdemir
    • 4
  • Emre Alhan
    • 3
  1. 1.Faculty of Medicine, Department of Pediatrics, Division of Intensive Care UnitÇukurova UniversityAdanaTurkey
  2. 2.Faculty of Medicine, Department of Pediatrics, Division of NeonatologyÇukurova UniversityAdanaTurkey
  3. 3.Faculty of Medicine, Department of Pediatrics, Division of Infectious DiseaseÇukurova UniversityAdanaTurkey
  4. 4.Faculty of Medicine, Department of BiostatisticsÇukurova UniversityAdanaTurkey

Personalised recommendations